Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
INACTIVE COMPANY
 
My Lists

Aerovance

2929 7th Street #120
Berkeley, CA 94710
USA
510-549-5500
Website Company Summary Management Team
Team

Management: Mark L. Perry (CEO) Lisa Arai (Director of Clinical Operations) Babatunde A. Otulana (Chief Medical Officer);  Richard Fuller (EVP R&D);  Robert W. Kuhn (CTO)
Company

Business description: Aerovance is dedicated to developing and commercializing biologic products for respiratory diseases. Bayer Pharmaceuticals Corp. has spun out the rights to two lead products to Aerovance: an IL4/13 receptor antagonist for severe asthma entering Phase II studies and Bikunin, a recombinant therapeutic protein for cystic fibrosis and chronic obstructive pulmonary disease on track for the filing of an investigational new drug application. Bayer also spun out additional research-stage and preclinical programs in respiratory disease to Aerovance.
Capital

Rounds: 4
Recent fundings: Apr 2009   Mar 2007
Capital raised: 130.0M
Last Round: 38.0M
Ownership: Private  
VCs include: Alta PartnersApax PartnersBurrillAndCompanyClarus VenturesLehman BrothersProQuest Investments;  Bellevueset Management;  NGN Capital
Corporate investors: Bayer Pharmaceuticals

Last Tweets


 

Last Mentions


Overview
Record updated: Aug 2009
Sector: Biotech
Rounds: 4
Recent fundings: Apr 2009   Mar 2007
Capital raised: 130.0M
Last Round: 38.0M
Ownership: Private